Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Leases (2023 - 2025)

Historic Operating Leases for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Q3 2025 value amounting to $8.4 million.

  • Centessa Pharmaceuticals' Operating Leases fell 639.69% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year decrease of 639.69%. This contributed to the annual value of $8.3 million for FY2024, which is 677.32% down from last year.
  • Centessa Pharmaceuticals' Operating Leases amounted to $8.4 million in Q3 2025, which was down 639.69% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Operating Leases registered a high of $9.7 million during Q1 2023, and its lowest value of $8.3 million during Q4 2024.
  • Over the past 3 years, Centessa Pharmaceuticals' median Operating Leases value was $9.0 million (recorded in 2024), while the average stood at $9.0 million.
  • Over the last 5 years, Centessa Pharmaceuticals' Operating Leases had its largest YoY gain of 423.23% in 2024, and its largest YoY loss of 677.32% in 2024.
  • Over the past 3 years, Centessa Pharmaceuticals' Operating Leases (Quarter) stood at $8.9 million in 2023, then decreased by 6.77% to $8.3 million in 2024, then rose by 1.89% to $8.4 million in 2025.
  • Its Operating Leases was $8.4 million in Q3 2025, compared to $8.6 million in Q2 2025 and $8.7 million in Q1 2025.